SEC Form 4 · accession 0001104659-19-012547
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M Siebert
Director
Period of report
Aug 20, 2018
Accepted (ET)
Mar 4, 2019 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2018 | M | 8,722 | $7.90 | A | 28,285 | D | |
| Common Stock | Aug 20, 2018 | M | 7,457 | $9.24 | A | 35,742 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy) | $7.90 | Aug 20, 2018 | M | 8,722 | D | Feb 5, 2014 | Feb 5, 2023 | Common Stock | 8,722 | 0 | D |
| Director Stock Option (Right to Buy) | $9.24 | Aug 20, 2018 | M | 7,457 | D | Jan 21, 2015 | Jan 21, 2024 | Common Stock | 7,457 | 0 | D |